In brief
- A study published in Translational Psychiatry analyzes peripheral methylation in two distinct cohorts; it is not a randomized ketamine-versus-MDMA comparison.
- No individual CpG survived FDR correction, although aggregated genes and pathways showed signals. These are not demonstrated brain changes or validated clinical markers.
- The authors present this as a first step toward potential biomarkers for treatment response, though they caution that the sample sizes are small (20 and 16 people) and the results are preliminary.
Ketamine and MDMA are investigated in clinical contexts such as treatment-resistant depression, but this report concerns peripheral methylation associations. A study in Translational Psychiatry, using two different cohorts, did not randomly assign people to ketamine versus MDMA or directly measure brain changes.
What was measured and how
The work, designed as a brain-targeted epigenome-wide association study (BEWAS), analyzed blood samples from twenty people treated with ketamine and saliva samples from sixteen people who participated in MDMA trials, before and after treatment. Blood was collected ten days after ketamine, while saliva was collected six to eight weeks after MDMA with psychotherapy. Diagnoses and protocols also varied. Selecting brain-relevant genes does not turn blood or saliva into a brain biopsy; BEWAS narrows the testing space but does not itself validate a biomarker.
Overlapping, yet distinct, footprints
The primary paper describes 8,344 and 11,544 nominally associated CpGs (p<0.05), respectively for ketamine and MDMA; no individual CpG survived FDR correction. The earlier report’s 1,210 and 2,074 modified positions are not ratified here. At a different level, gene aggregation identified 405 and 346 genes after FDR, and enrichment 169 and 183 pathways. Sites, genes and pathways must not be conflated or plasticity annotations turned into demonstrated brain plasticity. Shared or differing methylation directions do not establish distinct molecular causes of clinical efficacy.
What this implies
These are small samples with different tissues, timing, diagnoses and therapeutic contexts. Differences cannot all be attributed to drug, shown to persist or shown to cause improvement. Authors state that gene expression, neuroplastic capacity and immune state cannot be inferred from these data. Smoking and ethnicity were not adjustment covariates. These are exploratory associations requiring replication and validation, not a test for selecting treatment or predicting individual response.
Source
- Translational Psychiatry (Nature Portfolio). Brain-targeted epigenetic effects of two emerging psychoplastogens: ketamine & MDMA. Translational Psychiatry, July 11, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
